First Time Loading...

Caribou Biosciences Inc
NASDAQ:CRBU

Watchlist Manager
Caribou Biosciences Inc Logo
Caribou Biosciences Inc
NASDAQ:CRBU
Watchlist
Price: 3.76 USD -2.34% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

CRBU's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. [ Read More ]

The intrinsic value of one CRBU stock under the Base Case scenario is 4.9 USD. Compared to the current market price of 3.76 USD, Caribou Biosciences Inc is Undervalued by 23%.

Key Points:
CRBU Intrinsic Value
Base Case
4.9 USD
Undervaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Caribou Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CRBU stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Caribou Biosciences Inc

Provide an overview of the primary business activities
of Caribou Biosciences Inc.

What unique competitive advantages
does Caribou Biosciences Inc hold over its rivals?

What risks and challenges
does Caribou Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Caribou Biosciences Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Caribou Biosciences Inc.

Provide P/S
for Caribou Biosciences Inc.

Provide P/E
for Caribou Biosciences Inc.

Provide P/OCF
for Caribou Biosciences Inc.

Provide P/FCFE
for Caribou Biosciences Inc.

Provide P/B
for Caribou Biosciences Inc.

Provide EV/S
for Caribou Biosciences Inc.

Provide EV/GP
for Caribou Biosciences Inc.

Provide EV/EBITDA
for Caribou Biosciences Inc.

Provide EV/EBIT
for Caribou Biosciences Inc.

Provide EV/OCF
for Caribou Biosciences Inc.

Provide EV/FCFF
for Caribou Biosciences Inc.

Provide EV/IC
for Caribou Biosciences Inc.

Show me price targets
for Caribou Biosciences Inc made by professional analysts.

What are the Revenue projections
for Caribou Biosciences Inc?

How accurate were the past Revenue estimates
for Caribou Biosciences Inc?

What are the Net Income projections
for Caribou Biosciences Inc?

How accurate were the past Net Income estimates
for Caribou Biosciences Inc?

What are the EPS projections
for Caribou Biosciences Inc?

How accurate were the past EPS estimates
for Caribou Biosciences Inc?

What are the EBIT projections
for Caribou Biosciences Inc?

How accurate were the past EBIT estimates
for Caribou Biosciences Inc?

Compare the revenue forecasts
for Caribou Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Caribou Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Caribou Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Caribou Biosciences Inc compared to its peers.

Compare the P/E ratios
of Caribou Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Caribou Biosciences Inc with its peers.

Analyze the financial leverage
of Caribou Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Caribou Biosciences Inc.

Provide ROE
for Caribou Biosciences Inc.

Provide ROA
for Caribou Biosciences Inc.

Provide ROIC
for Caribou Biosciences Inc.

Provide ROCE
for Caribou Biosciences Inc.

Provide Gross Margin
for Caribou Biosciences Inc.

Provide Operating Margin
for Caribou Biosciences Inc.

Provide Net Margin
for Caribou Biosciences Inc.

Provide FCF Margin
for Caribou Biosciences Inc.

Show all solvency ratios
for Caribou Biosciences Inc.

Provide D/E Ratio
for Caribou Biosciences Inc.

Provide D/A Ratio
for Caribou Biosciences Inc.

Provide Interest Coverage Ratio
for Caribou Biosciences Inc.

Provide Altman Z-Score Ratio
for Caribou Biosciences Inc.

Provide Quick Ratio
for Caribou Biosciences Inc.

Provide Current Ratio
for Caribou Biosciences Inc.

Provide Cash Ratio
for Caribou Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Caribou Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Caribou Biosciences Inc?

What is the current Free Cash Flow
of Caribou Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Caribou Biosciences Inc.

Financials

Balance Sheet Decomposition
Caribou Biosciences Inc

Current Assets 338.8m
Cash & Short-Term Investments 328.8m
Receivables 3.9m
Other Current Assets 6.2m
Non-Current Assets 93.4m
Long-Term Investments 51.3m
PP&E 40.5m
Other Non-Current Assets 1.6m
Current Liabilities 28.3m
Accounts Payable 3.1m
Accrued Liabilities 20.9m
Other Current Liabilities 4.3m
Non-Current Liabilities 35.5m
Other Non-Current Liabilities 35.5m
Efficiency

Earnings Waterfall
Caribou Biosciences Inc

Revenue
34.5m USD
Operating Expenses
-150.5m USD
Operating Income
-116.1m USD
Other Expenses
14m USD
Net Income
-102.1m USD

Free Cash Flow Analysis
Caribou Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CRBU Profitability Score
Profitability Due Diligence

Caribou Biosciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Positive Revenue Growth Forecast
28/100
Profitability
Score

Caribou Biosciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

CRBU Solvency Score
Solvency Due Diligence

Caribou Biosciences Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
72/100
Solvency
Score

Caribou Biosciences Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRBU Price Targets Summary
Caribou Biosciences Inc

Wall Street analysts forecast CRBU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRBU is 20.4 USD with a low forecast of 10.1 USD and a high forecast of 31.5 USD.

Lowest
Price Target
10.1 USD
169% Upside
Average
Price Target
20.4 USD
443% Upside
Highest
Price Target
31.5 USD
738% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CRBU Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CRBU Price
Caribou Biosciences Inc

1M 1M
-26%
6M 6M
-2%
1Y 1Y
-11%
3Y 3Y
-77%
5Y 5Y
-77%
10Y 10Y
-77%
Annual Price Range
3.76
52w Low
3.58
52w High
8.26
Price Metrics
Average Annual Return -31.49%
Standard Deviation of Annual Returns 35.86%
Max Drawdown -88%
Shares Statistics
Market Capitalization 332.6m USD
Shares Outstanding 90 314 496
Percentage of Shares Shorted 11.84%

CRBU Return Decomposition
Main factors of price return

What is price return decomposition?

CRBU News

Other Videos

Last Important Events
Caribou Biosciences Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Caribou Biosciences Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Caribou Biosciences Inc Logo
Caribou Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

332.6m USD

Dividend Yield

0%

Description

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.

Contact

CALIFORNIA
Berkeley
2929 7th St Ste 105
+15109826030.0
http://cariboubio.com/

IPO

2021-07-23

Employees

97

Officers

Co-Founder, CEO, President & Director
Dr. Rachel E. Haurwitz Ph.D.
Chief Business Officer
Ms. Ruhi A. Khan M.B.A.
CFO & Principal Accounting Officer
Mr. Jason V. O'Byrne M.B.A.
Vice President of Operations & Information Technology
Mr. Daniel Poon
Chief Technology Officer
Mr. Timothy P. Kelly M.B.A.
Chief Scientific Officer
Dr. Steven B. Kanner Ph.D.
Show More
Vice President of Investor Relations & Corporate Communications
Ms. Amy Figueroa C.F.A.
Chief Legal Officer & Corporate Secretary
Ms. Barbara G. McClung Esq., J.D.
Chief People Officer
Ms. Reigin Zawadzki
Vice President of Finance & Controller
Mr. Ryan Fischesser
Show Less

See Also

Discover More
What is the Intrinsic Value of one CRBU stock?

The intrinsic value of one CRBU stock under the Base Case scenario is 4.9 USD.

Is CRBU stock undervalued or overvalued?

Compared to the current market price of 3.76 USD, Caribou Biosciences Inc is Undervalued by 23%.